Second interim analysis of the Global Investigation of Therapeutic Decisions in Unresectable HCC and of Its Treatment with Sorafenib (GIDEON): Sorafenib dosing and safety in U.S. patients.
Anthony B. El-Khoueiry
Consultant or Advisory Role - Bayer/Onyx
Honoraria - Bayer/Onyx
Research Funding - Bayer/Onyx; Bristol-Myers Squibb
Bilal Piperdi
Honoraria - Bayer/Onyx
Alec Goldenberg
No relevant relationships to disclose
Allen Lee Cohn
No relevant relationships to disclose
Jeff H. Geschwind
Consultant or Advisory Role - Bayer; Biocompatibles International; Guerbet; Nordion
Research Funding - Bayer; Biocompatibles International; CeloNova; ContextVision; Genentech; Nordion; Phillips Medical; RSNA
Jorge A. Marrero
Consultant or Advisory Role - Bayer/Onyx; Bristol-Myers Squibb
Research Funding - Bayer/Onyx; Bristol-Myers Squibb
Arun Sanyal
Employment or Leadership Position - AASLD (U)
Consultant or Advisory Role - Onyx (U)
Research Funding - Bayer/Onyx
Alan Paul Venook
Research Funding - Bayer/Onyx